Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-23-053138
Filing Date
2023-04-28
Accepted
2023-04-28 17:00:21
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A tm2313902d1_10ka.htm   iXBRL 10-K/A 183127
2 EXHIBIT 31.3 tm2313902d1_ex31-3.htm EX-31.3 3552
3 EXHIBIT 31.4 tm2313902d1_ex31-4.htm EX-31.4 3788
  Complete submission text file 0001104659-23-053138.txt   433582

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA scps-20211231.xsd EX-101.SCH 3054
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE scps-20211231_lab.xml EX-101.LAB 36509
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scps-20211231_pre.xml EX-101.PRE 24012
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2313902d1_10ka_htm.xml XML 5322
Mailing Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE, SUITE 300 NEW YORK NY 10170 (212) 479-2513
Scopus BioPharma Inc. (Filer) CIK: 0001772028 (see all company filings)

EIN.: 821248020 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39788 | Film No.: 23867906
SIC: 2834 Pharmaceutical Preparations